SCHEMBL4145343

SCHEMBL4145343

Brc1n[nH]c2ccncc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 4/20 0.42
IDO1 P14902 1/20 0.41
LRRK2 Q5S007 1/20 0.41
PARP1 P09874 1/20 0.38
JAK2 O60674 2/20 0.37
AXL P30530 2/20 0.37
PDPK1 O15530 1/20 0.37
CLK2 P49760 2/20 0.37
DYRK1A Q13627 2/20 0.37
DCLK1 O15075 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
CHEK2 O96017 1/20 0.37
CSF1R P07333 1/20 0.37
FER P16591 1/20 0.37
CDK2 P24941 1/20 0.37
MARK3 P27448 1/20 0.37
FLT4 P35916 1/20 0.37
FLT3 P36888 1/20 0.37
MAPK9 P45984 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31543546 1.00 ACHE (0.42) ACHEIDO1LRRK2PARP1JAK2
SCHEMBL30632762 1.00 ACHE (0.42) ACHEIDO1LRRK2PARP1JAK2
SCHEMBL658647 0.83 CHUK (0.44) IDO1LRRK2PARP1AXLDYRK1A
SCHEMBL30269881 0.77 JAK2 (0.55) ACHEIDO1LRRK2PARP1JAK2
SCHEMBL5267583 0.77 JAK2 (0.55) ACHEIDO1LRRK2PARP1JAK2
SCHEMBL9251358 0.76 CLK2 (0.54) IDO1LRRK2JAK2AXLPDPK1
SCHEMBL6886163 0.75 ACHE (0.42) ACHEIDO1LRRK2PARP1JAK2
SCHEMBL19332754 0.75 ACHE (0.42) ACHEIDO1LRRK2PARP1JAK2
Hydrochloric Acid SCHEMBL31691957 0.75 JAK2 (0.53) ACHEIDO1LRRK2PARP1JAK2
SCHEMBL29760819 0.75 ACHE (0.42) ACHEIDO1LRRK2PARP1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090317-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 WO disclosed
WO-2026090300-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 WO disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
WO-2025101914-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS HAVING IMPROVED THERAPEUTIC INDEX AGAINST SOLID TUMORS MEKANISTIC THERAPEUTICS LLC (US) 2025-05-15 WO disclosed
EP-4522612-A1 TYK2 INHIBITORS Biogen MA Inc. (US) 2025-03-19 EP disclosed
EP-3405192-B1 BRUTON'S TYROSINE KINASE INHIBITORS ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) 2024-12-11 EP disclosed
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-07-18 US disclosed
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-07-18 US disclosed
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-07-18 US disclosed
US-20240083868-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS MEKANISTIC THERAPEUTICS, LLC 2024-03-14 US disclosed
EP-2489663-A1 Compounds as syk kinase inhibitors Almirall, S.A. (ES) 2012-08-22 EP disclosed
WO-2012106995-A1 RORGAMMAT INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-08-16 WO disclosed
EP-2487159-A1 RorgammaT inhibitors MSD Oss B.V. (NL) 2012-08-15 EP disclosed
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND OHI NORIHITO 2009-02-26 US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-7429609-B2 Pyrazole compound and medicinal composition containing the same EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-09-30 US disclosed
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-24 US disclosed
US-20050208582-A1 Pyrazole compounds and pharmaceutical compositions comprising the compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-09-22 US disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 ACHE 4790/4885IDO1 533/4885LRRK2 305/4885
US-20240239764-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS EGFR, ERBB2, ERBB3 ACHE 4848/4885IDO1 2650/4885LRRK2 176/4885
US-20090054397-A1 PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND CNKSR1, NR3C2, CSNK2B ACHE 3264/4885IDO1 3063/4885LRRK2 601/4885
US-20050261339-A1 Pyrazole compound and medicinal composition containing the same CNKSR1, NR3C2, CSNK2B ACHE 3331/4885IDO1 3135/4885LRRK2 556/4885
US-20240083868-A1 SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS EGFR, ERBB2, ERBB3 ACHE 4848/4885IDO1 2650/4885LRRK2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.